Hydroxychloroquine and Chloroquine Retinopathy

Browning, David J.

doi:10.1007/978-1-4939-0597-3

Cited by 64 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antimalarial drug chloroquine is known to exhibit broadspectrum antiviral activity [158]. It is a weak base (pK 1 = 8.1, pK 2 = 10.1), and the pH of lysosomes in the presence of chloro-quine increases from $4 to $6 [159]. This increase is thought to be responsible for the inhibition of the pH-dependent fusion step of viral entry.…”

Section: Endocytosis and Endosomal Fusion Blocking Agentmentioning

confidence: 99%

The A–Z of Zika drug discovery

Mottin

Borba

Braga

et al. 2018

Drug Discovery Today

View full text Add to dashboard Cite

show abstract

Section: Endocytosis and Endosomal Fusion Blocking Agentmentioning

confidence: 99%

The A–Z of Zika drug discovery

Mottin

Borba

Braga

et al. 2018

Drug Discovery Today

View full text Add to dashboard Cite

show abstract

“…After the oral administration of CQ and HCQ, they absorb completely within 2 to 4 h with slight variation among the subjects [ 32 , 33 ]. The mean absorption of both drugs is almost equal [ 34 ] and normally gets absorbed in the upper part of the intestinal tract [ 35 , 36 ]. CQ overdose could be treated when the subject is administered with charcoal orally by reducing absorption [ 37 ].…”

Section: Common Pharmacokinetics Profile Of Cq/hcqmentioning

confidence: 99%

The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review

Das

Ramachandran

Birangal

et al. 2021

Medicine in Drug Discovery

View full text Add to dashboard Cite

Recently, the pandemic outbreak of a novel coronavirus, officially termed as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), indicated by a pulmonary infection in humans, has become one of the most significant challenges for public health. In the current fight against coronavirus disease-2019, the medical and health authorities across the world focused on quick diagnosis and isolation of patients; meanwhile, researchers worldwide are exploring the possibility of developing vaccines and novel therapeutic options to combat this deadly disease. Recently, based on various small clinical observations, uncontrolled case studies and previously reported antiviral activity against SARS-CoV-1 chloroquine (CQ) and hydroxychloroquine (HCQ) have attracted exceptional consideration as possible therapeutic agents against SARS-CoV-2. However, there are reports on little to no effect of CQ or HCQ against SARS-CoV-2, and many reports have raised concerns about their cardiac toxicity. Here, in this review, we examine the chemistry, molecular mechanism, and pharmacology, including the current scenario and future prospects of CQ or HCQ in the treatment of SARS-CoV-2.

show abstract

Inhibitors of ZIKV Replication and Infection

2018

Zika Virus and Diseases

View full text Add to dashboard Cite

Hydroxychloroquine and Chloroquine Retinopathy

Cited by 64 publications

References 23 publications

The A–Z of Zika drug discovery

The A–Z of Zika drug discovery

The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review

Inhibitors of ZIKV Replication and Infection

Contact Info

Product

Resources

About